Later-Onset Hypertension Is Associated With Higher Risk of Dementia in Mild Cognitive Impairment

Abstract

To investigate the correlation between hypertension development and the progression of mild cognitive impairment (MCI) to dementia in middle-aged and elderly people. A population-based longitudinal cognition survey of people aged 55+ was conducted. The hypertension onset age was estimated by self-reported information and medical insurance card records. To study the effect of later-onset hypertension on dementia, the incidence of dementia was compared between the two groups. Of 277 hypertensive MCI participants without dementia, 56 (20.22%) progressed to dementia (MCIp) over the 6-year follow-up. The proportion of MCIp participants in the old-age-onset hypertension group (≥65 years) was higher than that in the middle-age-onset hypertension group (27.0 vs. 15.4%, respectively; X² = 5.538, P = 0.019). In the old-age-onset hypertension group, the proportion of MCIp without diabetes mellitus was higher than those with diabetes mellitus (24.7 vs. 12.6%, respectively; X² = 5.321, P = 0.021) and those with increased pulse pressure was higher than those without increased pulse pressure (33.3 vs. 15.4%, respectively; X² = 3.902, P = 0.048). However, the cox proportional hazard showed that older age was the only risk factor for MCIp (HR = 0.618, p = 0.000). These results suggest that individuals with later-onset hypertension may have greater cognition decline, even with blood pressure maintained at 130/80 mmHg with antihypertensive management.

Introduction

With increases in population aging, the number of individuals with dementia continues to rise, with ~47 million people worldwide in 2015, which is expected to triple by 2050 (1). The two most common types of dementia are Alzheimer's disease (AD) and vascular dementia (VaD), accounting for ~80% (1–3). Mild cognitive impairment (MCI) is an intermediate transition stage between normal aging and dementia that is characterized by mild impairments in cognitive function without a decline in daily living or social functioning, and previous studies have shown that all MCI eventually progressed to dementia (MCI progression, MCIp) after 9 years (4). A multicenter study performed in China from 2008 to 2009 showed that the prevalence rates of MCI and dementia (in those >65 years old) were as high as 20.8 and 5.14%, respectively (5).

Hypertension is another disease that compromises the activites of daily living in the elderly population (6, 7). In the last 20 years, several studies have found that hypertension is a risk factor not only for AD but also for MCI (2, 7–10). In a 2-year follow-up study of 385 MCI patients, Goldstein et al. (11) showed that cognitive function (such as attention, executive function, and naming) of subjects with hypertension, compared to subjects without hypertension, significantly declined, especially in those with systolic blood pressure (SBP) ≥ 140 mmHg, or diastolic blood pressure (DBP) ≥ 90 mmHg. In other words, hypertension is a risk factor for MCIp. To date, there have been no confirmed effects of nootropic drugs on dementia, whereas hypertension is a very important controllable vascular risk factor (2). Therefore, it is crucial to quickly identify and manage high-risk patients with hypertension, which will subsequently prevent dementia.

The incidence of dementia has been related to the age of onset of hypertension. Numerous studies have shown that hypertension in middle-aged individuals is associated with increased dementia 20 or 30 years later, but the relationship to later-onset hypertension (≥65 years) is uncertain (9, 12). For example, some studies have found that hypertension is independently associated with cognitive impairment in later life and that cognitive function declines with increasing SBP, especially SBP ≥ 180 mmHg (13–15). In Yuan's study, the relationship between the decline in cognition as SBP increased was shaped like a “hockey stick (i.e., a gradual decline followed by a dramatic decrease)” (16). It was also confirmed in a cross-sectional survey that not only the proportion of hypertension (76.5 vs. 59.3%) but also the SBP level was higher in the dementia group than in the MCI group (15). However, some previous studies showed that hypertension did not necessarily increase the risk of dementia (2, 17–22). A 10-year follow-up (averaging 2.8 years) study of 559 individuals who were over 90 years old conducted by Corrada et al. (17) found that the risk of dementia in hypertensive patients aged 80 and 90 years was lower than that in non-hypertensive patients. Nevertheless, a high SBP level was possibly associated with an increased risk of dementia for individuals <75 years old, and this was not the case for those >80 years old (19–22). Moreover, it was not the high SBP level but the increased pulse pressure (PP) that was negatively correlated with cognition (23).

Our previous epidemiological investigation found that MCI in individuals with new-onset hypertension (≥60 years old) had a higher rate of dementia (24). We proposed the hypothesis that there may be a particular age (between 55 and 75 years old) when hypertension is particularly harmful to cognitive function. Our objective was to evaluate the association between the later onset of hypertension and the risk of all-cause dementia in a population-based cohort of individuals.

Materials and Methods

Ethics Statement

The research project was examined and approved by the Ethics Committee of the Mental Health Center of Pudong New Area, Shanghai (2017005). The guardians of all the dementia individuals provided ethical consent for their participation.

Subjects

The current research was carried out in Pudong district in Shanghai. We analyzed elderly individuals with MCI (age ≥ 55 years old) who had participated in a survey from June 2011 to June 2012 (No. PKJ2010-Y26) and were successfully contacted for a subsequent survey in 2017. All participants signed informed consent forms. Only those sufficiently educated with adequate audiovisual skills that were needed to complete the necessary examinations were included.

Based on the age of onset of hypertension, the participants were divided into the old-aged group (onset age ≥ 65 years) and the middle-aged group (onset age <65 years).

MCI and Dementia Diagnostic Criteria

MCI was diagnosed using the revised Mayo Clinic criteria: (1) elderly individuals consciously exhibited memory loss, especially those with memory impairment for more than 3 months; (2) overall cognitive function was normal through the Mini-Mental State Examination (MMSE total score: illiterate subjects > 17, with primary school education > 20 points, and others > 24 points); (3) clinical dementia rating (CDR) score reached a level of 0.5; (4) Montreal Cognitive Assessment Scale (MoCA) scores were ≤ 26; (5) the patient had normal function in daily life; and (6) the patient did not meet the diagnostic criteria for dementia (25, 26).

The criteria for dementia were as follows. (1) MMSE test scores were ≤ 17 for illiterate subjects, ≤ 20 points for subjects with primary school education, and ≤ 24 points for subjects with middle school education or above (27); (2) the subjects met the above criterion without definite blindness or speech difficulties.

Cognitive and Other Neuropsychological Assessments

Subjects received cognitive and other neuropsychological assessments using the following scales where possible: (1) Mini-Mental State Examination (MMSE) scale (27), (2) Montreal Cognitive Assessment (MoCA) (26), (3) Hamilton Depression Scale (HAMD-17) (28), (4) Hachinski ischemic scale (HIS) (29), (5) activities of daily life scale (ADL) (30), and (6) clinical dementia rating (CDR) scale (31).

Diagnosis and Treatment of Hypertension

The diagnosis, duration, age of onset, stage, and treatment of hypertension were collected based on self-reports from the elderly individuals and examination of their medical insurance card records. The treatment of hypertension was as follows, 34.0% (n = 91) patients take calcium channel blocker, 11.6% (n = 31) patients take angiotensin receptor blockers, and 7.1% (n = 19) patients take other medicines, whereas 41% (n = 110) patients unregularly take medicines; 6.3% (n = 17) patients take no medicines.

Additional Variables

Other aspects of the medical histories reported at the baseline visit and considered potential confounders included stroke, transient ischemic attack, diabetes mellitus (DM), heart disease, and depression. Heart disease included any of the following diseases or surgeries: coronary artery disease, myocardial infarction, atrial fibrillation or other arrhythmias, heart valve disease, congestive heart failure, coronary artery bypass, or pacemaker placement. The highest level of education attained, marital status, and occupation were also recorded.

Statistical Approach

Data were analyzed using the Statistical Package for Social Sciences (version 19.0; SPSS, IBM, Chicago, IL, USA). Continuous variables were tested for normality by the one-sample Kolmogorov-Smirnov-test. Continuous variables are expressed as the mean ± SD or median (range) as per distribution type, and categorical data are expressed as frequency and percentages. Statistical analyses were performed using independent samples t-tests for normal data and Mann-Whitney U-tests for non-normal data. Categorical data were analyzed by the chi-square-test. Cox proportional hazard was conducted to identify the determinants of the MCIp outcome. A P-value of < 0.05 was considered statistically significant.

Results

Follow-Up Outcomes of Hypertensive MCI Individuals in the Community

There were 56 individuals (20.22%) who progressed to dementia (MCIp), while 221 (79.78%) remained stable (MCIs). In comparison with the MCIs individuals, the MCIp individuals demonstrated significantly worse performance on the CDR and ADL scales (p < 0.01). In addition, the MCIp individuals were more likely to be single (p = 0.022; Table 1), which could be both the reason and consequence of cognitive function deterioration. Next, all individuals were divided into two groups according to the onset time of hypertension: the proportion of MCIp participants in the old-age-onset hypertension group (≥65 years) was significantly higher than that in the middle-age-onset hypertension group (27.0 vs. 15.4%, respectively; X² = 5.538, p = 0.019). However, this may have been because the old-age-onset group were older than the middle-age-onset group (77.75 ± 6.75 vs. 70.45 ± 6.41, respectively, p < 0.001). For those without DM, the old-age-onset hypertension group showed a higher proportion of MCIp outcomes than the middle-age-onset group (26.5 vs. 10.6%, respectively; X² = 9.071, P = 0.003) (Table 2), and the frequency of MCIp in those with increased pulse pressure was higher than in those without increased pulse pressure (33.3 vs. 15.4%, respectively; X² = 3.902, P = 0.048). Here, increased pulse pressure refers to the value of systolic pressure minus diastolic pressure being higher than 60 mmHg. This result implied that in those individuals with a later onset of hypertension, increased pulse pressure was associated with the progression of cognitive impairment.

Cox Proportional Hazard of Cognitive Function Deterioration in MCI

The cox proportional hazard model was fitted to analyze the determinants of the MCI outcome at follow-up (MCIp = 0, MCIs = 1). Demographic data and variables such as hypertension, age at onset of hypertension, blood pressure grouping, and pulse pressure were taken as independent variables in the model. The variable assignment for the cox proportional hazard analysis is listed in Table 3. The results showed that age (P = 0.000, HR = 0.618) and BMI (P = 0.024, HR = 1.151) were the independent determinant of MCI outcome at follow-up and that patients with a age <80 and higher BMI were more likely to maintain cognitive function (Table 4 and Figure 1). Other factors demonstrated no significant association with MCIp (P > 0.05).

Figure 1

Discussion

Main Findings

The Proportion of MCIp Was Higher in the Group With Hypertension Onset ≥ 65 Years

In this prospective study of 277 MCI participants aged 73.48 ± 7.47 years having a late onset of hypertension (≥65 years) was related to a higher dementia risk compared with those with an onset of hypertension in middle age. This increased risk was limited to participants who reported a mean SBP of 130/80 mmHg. In addition, the differences disappeared after stratification according to age and BMI, SBP, and DBP levels. To our knowledge, our study is the first to report blood pressure levels and to include hypertension by age of onset.

Some researchers have found that an increased risk of dementia was related to the increase in SBP in the group under 75 years old (17). The risk of cognitive impairment increased by 1.17 times when SBP was 130–139 mmHg; however, the risk increased to 1.54 times when SBP was ≥180 mmHg (16). The results from a 3.8-year follow-up of individuals with hypertension (n = 2,800) showed that incidences of MCI and dementia decreased by 15% with intensive control of blood pressure (SBP < 120 mmHg) compared with the standard control group (SB < 140 mmHg) (HR = 0.85, 95% CI = 0.74–0.97, P = 0.02) (32); moreover, a statistically significant reduced risk of MCI and dementia was found in the intensive group (SBP = 120 mmHg) <75 years old (33).

The results of this study are not consistent with some previously published results. The reasons may be as follows: First, the average age of the participants in this study was 73 years with a mean SBP of 130/80 mmHg, 57% of them were <75 years old, 8 patients (2.89%) had SBP < 120 mmHg and 8 (2.89%) had SBP ≥ 160 mmHg. Our sample size was relatively small. Second, through medication management with a goal in the normal range (130/80 mmHg), the proportion of MCIp was different between the two groups, suggesting that aggressively lowering SBP may not be beneficial in elderly individuals (2). Similar findings were found in a long-term large-sample study (n = 1,440; 8-year follow-up) where the risk of dementia increased by 2.4 times when blood pressure was <140/90 mmHg in middle- to old-aged individuals with hypertension.

Furthermore, some studies have found that the relationship between the risk of dementia and the increase in SBP was not yet clear for those older than 85 years (17). After 10 years of follow-up (average 2.8 years, n = 559), Corrada et al. (17) reported that the risk of dementia in patients with new-onset hypertension and aged 80+ and 90+ years was lower than that in non-hypertensive patients (HR 0.54 and 0.37, P = 0.04 and 0.004, respectively). The results suggested that the relationship between hypertension and dementia in the elderly cohort was different from that in the middle-aged cohort. Hypertension may be a result of compensatory responses of the body. That is, the etiology of hypertension is similar to that of dementia, but the clinical symptoms occur at different times.

In addition, the cognitive impacts of middle-aged hypertension can only be followed up and analyzed after excluding cerebrovascular accidents (21); that is, there is bias in the samples. Patients with middle-aged-onset hypertension have severe conditions that make it difficult to detect the impact of hypertension on AD because of cerebrovascular damage such as stroke (22). In addition, other community-based studies have found that middle-aged hypertension was associated with MCI and dementia at the age of 70–90 (more strongly associated with dementia) (23). These data suggest that this part of the population did not go through the MCI stage and directly entered the dementia stage, which may have contributed to sample bias.

However, the results of the cox proportional hazard analysis failed to identify age of hypertension onset, blood pressure and increased pulse pressure as risk factors for MCI deterioration, and only older age was identified as a risk factor. This is consistent with the results of other studies confirming that old age is the main risk factor for dementia (34). We found that the proportion of MCIp was higher in the group with hypertension onset ≥ 65 years. It is worth mentioning that univariate analyses and cox proportional hazard analyses can have inconsistent conclusions. When comparing the two analysis methods, the results implied that there was indeed an association between onset age and MCIp, but the relationship was not strong enough to be observed in both methods. However, this is the first study reporting that the age of hypertension onset is a risk factor, and we believe that when more data are accumulated, this variable can be used to help predict MCIp.

The Proportion of MCIp Was Higher in the Group Without Diabetes Mellitus

Another finding of our study was that for hypertensive MCI individuals without DM, the incidence of MCIp in the old-age group was 1.96 times higher than that in the middle-age group. One meta-analysis also found that the ability of cerebrovascular risk factors to predict dementia/AD in the old-age group (average age of 72.3–82.5 years) was significantly reduced compared with younger age groups (35). That is, cerebrovascular diseases such as hypertension, diabetes, and hyperlipidemia did not necessarily increase the risk of dementia. A large-sample survey of community-based individuals in a brain magnetic resonance imaging (MRI) follow-up study (n = 2,367) revealed that cerebrovascular risk factors such as white matter degeneration, hypertension, diabetes, and smoking were associated with aging and contributed to dementia, although the age range of this survey was 20–90 years (19). It should be noted that only 61 cases (22.02%) of DM in this study may have resulted in an insufficient sample size, which made it difficult to identify significant differences. In addition, in individuals with MCI aged 73.48 (SD = 7.47) years, the pathogenesis of DM may be different from that in middle-aged individuals, so the effect of DM on dementia may also be different.

The Association Between MCIp and Higher Pulse Pressure

We noticed that the incidence of MCIp was higher in the groups of patients that had higher pulse pressure. Pulse pressure is a sign of arterial stiffness. It was previously shown that pulse pressure was associated not with hypertension and apolipoprotein E4 but with the deposition of beta-amyloid plaques in the brain (23). In other words, pulse pressure is closely related to aging.

Jefferson et al. (36) used pulse wave velocity (PWV, m/sec) to measure aortic stiffness and found that decreases in regional cerebral blood flow were related to increases in arterial stiffness despite the existence of cerebral blood flow reserve capacity. Follow-up and cross-sectional clinical studies have confirmed that increased pulse pressure increases the risk of dementia (including vascular dementia and AD), which indicates that medications may lead to occult hypotension and cerebral hypoperfusion (37).

MCIp Did Not Benefit From Antihypertensive Therapy

Regarding the prevention of dementia by antihypertensive therapy, some studies have suggested that the risk of dementia was increased by the potential hypotension induced by antihypertensive therapy due to impaired vascular regulation mechanism in elderly individuals (38–40). A 16-week follow-up study suggested that people over 75 years old with MCI who stopped taking antihypertensive drugs did not develop cognitive function deterioration (40). They did not explicitly state whether all MCI cases had late-onset hypertension, and their follow-up time was too short. A multicenter study found that hypertensive patients over 65 years of age showed a temporary increase in blood pressure 4 months after reducing antihypertensive medicine but recovered to 134 mmHg in 9 months, while the control group (without reducing drugs) had an increased risk of emergency hospitalization (20). Animal experiments have also suggested that sartan therapy can improve cognition in aged rats (41, 42). However, clinical studies, as well as meta-analyses, have reported that although antihypertensive therapy can reduce systolic or DBP, it does not reduce the incidence of dementia (12, 17, 23, 43). Taken together, for the prevention of dementia in elderly individuals with hypertension, there are many studies that still need to be conducted.

Besides, the result suggested that participants with higher BMI were more likely to maintain cognitive function. However, it is still early to tell the parameter can be protective factors, we cannot distinguish the actual BMI and the BMI decrease due to osteoporosis and malnutrition, which can confound the treatment of hypertension and DM.

Conclusion

These results suggest that individuals with later-onset hypertension may have greater cognition decline, even in patients with blood pressure maintained at 130/80 mmHg with antihypertensive management.

Research Limitations

First, 277 elderly people with hypertension in the MCI community were followed up prospectively. The sample size was small, and the age distribution was uneven. The follow-up time was 6 years. There might have been sample bias that affected the proportion of MCIp to some extent.

Second, the survey of occupational mental activity, post-retirement economic life, lifestyle, and other factors in the MCI population with hypertension was not detailed enough, and the influence of an insufficient sample size also had some influence on the results of the study.

Third, the diagnosis of dementia in this study sample did not combine detection with imaging and cerebral spinal fluid (CSF) biochemical indicators without classification by Alzheimer's disease, Lewy bodies dementia, Dementia associated with parkinsonism, etc. And the mental state assessed without a “comprehensive” neuropsychological battery. The history and examination of hypertension were mainly provided by the community elderly individuals and medical record cards. There was no 24-h ambulatory blood pressure monitoring, which may have introduced some bias and had a certain impact on the objectivity of the results. So there were several confounders not considered in the analysis (i.e., serum lipids concentration, smoking, and white matter lesions burden at the MRI).

Research Significance

First, the results of the current investigation showed that MCI patients with hypertension with an average age of ~73 years old were prone to develop dementia, which suggests that the administration of antihypertensive drugs for hypertension in this population (≥65 years old) should be comprehensively considered. Because of the different mechanisms underlying hypertension, maintaining blood pressure at 130/80 mmHg may not have a positive effect regarding the protection of cognitive function. Second, this study showed that pulse pressure had a negative effect regarding the protection of cognitive function. In the group with increased pulse pressure, the proportion of the elderly patients progressing to dementia was higher than that of the middle-aged patients. This suggests that the pathogenesis of hypertension in older patients may be different than in middle-aged patients and that the effect of increased pulse pressure on cerebrovascular function also increased with age. Therefore, increased pulse pressure may be one of the risk factors for dementia. In the future, it is necessary to expand the research sample size and improve the experimental methods for further confirmation.

References

• 1.

  LivingstonGSommerladAOrgetaVCostafredaSGHuntleyJAmesDet al. Dementia prevention, intervention, and care. Lancet. (2017) 390:2673–734. 10.1016/S0140-6736(17)31363-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 2.

  TadicMCuspidiCHeringD. Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden. BMC Cardiovasc Disord. (2016) 16:208. 10.1186/s12872-016-0386-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 3.

  ChanKYWangWWuJJLiuLTheodoratouECarJet al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet. (2013) 381:2016–23. 10.1016/S0140-6736(13)60221-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 4.

  WardAArrighiHMMichelsSCedarbaumJM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement. (2012) 8:14–21. 10.1016/j.jalz.2011.01.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 5.

  JiaJWangFWeiCZhouAJiaXLiFet al. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement. (2014) 10:1–9. 10.1016/j.jalz.2013.01.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 6.

  SierraCDoménechMCamafortMCocaA. Hypertension and mild cognitive impairment. Curr Hypertens Rep. (2012) 14:548–55. 10.1007/s11906-012-0315-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 7.

  Lazo-PorrasMOrtiz-SorianoVMoscoso-PorrasMRunzer-ColmenaresFMMálagaGJaime MirandaJ. Cognitive impairment and hypertension in older adults living in extreme poverty: a cross-sectional study in Peru. BMC Geriatr. (2017) 17:250. 10.1186/s12877-017-0628-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 8.

  ZuoMGanCLiuTTangJDaiJHuX. Physical predictors of cognitive function in individuals with hypertension: evidence from the CHARLS basline survey. West J Nurs Res. (2019) 41:592–614. 10.1177/0193945918770794

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 9.

  WeiJYinXLiuQTanLJiaC. Association between hypertension and cognitive function: a cross-sectional study in people over 45 years old in China. J Clin Hypertens (Greenwich). (2018) 20:1575–83. 10.1111/jch.13393

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 10.

  SmithEEMuzikanskyAMcCrearyCRBatoolSViswanathanADickersonBCet al. Impaired memory is more closely associated with brain beta-amyloid than leukoaraiosis in hypertensive patients with cognitive symptoms. PLoS ONE. (2018) 13:e0191345. 10.1371/journal.pone.0191345

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 11.

  GoldsteinFCLeveyAISteenlandNK. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc. (2013) 61:67–73. 10.1111/jgs.12067

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 12.

  HarrisonJKVan Der WardtVConroySPStottDJDeningTGordonALet al. New horizons: the management of hypertension in people with dementia. Age Ageing. (2016) 45:740–6. 10.1093/ageing/afw155

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 13.

  GorelickPBScuteriABlackSEDecarliCGreenbergSMIadecolaCet al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. (2011) 42:2672–713. 10.1161/STR.0b013e3182299496

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 14.

  HaringBLengXRobinsonJJohnsonKCJacksonRDBeythRet al. Cardiovascular disease and cognitive decline in postmenopausal women: results from the women's health initiative memory study. J Am Heart Assoc. (2013) 2:e000369. 10.1161/JAHA.113.000369

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 15.

  LiangXShanYDingDZhaoQGuoQZhengLet al. Hypertension and high blood pressure are associated with dementia among chinese dwelling elderly: the Shanghai aging study. Front Neurol. (2018) 9:664. 10.3389/fneur.2018.00664

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 16.

  YuanJQLvYBChenHSGaoXYinZXWangWTet al. Association between late-life blood pressure and the incidence of cognitive impairment: a community-based prospective cohort study. J Am Med Dir Assoc. (2019) 20:177–82.e2. 10.1016/j.jamda.2018.05.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 17.

  CorradaMMHaydenKMPaganini-HillABullainSSDeMossJAguirreCet al. Age of onset of hypertension and risk of dementia in the oldest-old: the 90+ study. Alzheimers Dement. (2017) 13:103–10. 10.1016/j.jalz.2016.09.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 18.

  Alzheimer'sAssociation. Alzheimer's disease facts and figures. Alzheimers Dement. (2017) 13:325–73. 10.1016/j.jalz.2017.02.001

  • CrossRef
  • Google Scholar
  • View reference in article

• 19.

  PengSLChenXLiYRodrigueKMParkDCLuH. Age-related changes in cerebrovascular reactivity and their relationship to cognition: a four-year longitudinal study. Neuroimage. (2018) 174:257–62. 10.1016/j.neuroimage.2018.03.033

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 20.

  GullaCFloEKjomeRLHuseboBS. Deprescribing antihypertensive treatment in nursing home patients and the effect on blood pressure. J Geriatr Cardiol. (2018) 15:275–83. 10.11909/j.issn.1671-5411.2018.04.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 21.

  SharifiFHedayatMFakhrzadehHJafar MahmoudiMGhaderpanahiMMirarefinMet al. Hypertension and cognitive impairment: Kahrizak elderly study. Int J Gerontol. (2011) 5:212–6. 10.1016/j.ijge.2011.12.001

  • CrossRef
  • Google Scholar
  • View reference in article

• 22.

  Alzheimer'sAssociation. Alzheimer's disease facts and figures. Alzheimers Dement. (2018) 14:367–429. 10.1016/j.jalz.2018.02.001

  • CrossRef
  • Google Scholar
  • View reference in article

• 23.

  LimaNKC. Hypertension and cognition decline: is there an ultimate link?J Clin Hypertens (Greenwich). (2018) 20:1584–6. 10.1111/jch.13401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 24.

  QinHYZhuBGWangLGuoYCaoZCHuCP. Follow-up investigation of the effect of the new-onset and untreated hypertension on the elderly patients with mild cognitive impairment in community. Chin Gen Pract. (2020) 23:1640–53. 10.12114/j.issn.1007-9572.2019.00.785

  • CrossRef
  • Google Scholar
  • View reference in article

• 25.

  LuisCALoewensteinDAAcevedoABarkerWWDuaraR. Mild cognitive impairment: directions for future research. Neurology. (2003) 61:438–44. 10.1212/01.WNL.0000080366.90234.7F

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 26.

  ChenJYeZRYuanMFangY. The application and progression of the montreal cognitive assessment in mild cognitive impairment. Chin J Psvchiatr. (2017) 50:386–9. 10.3760/cma.j.issn.1006-7884.2017.05.01

  • CrossRef
  • Google Scholar
  • View reference in article

• 27.

  Gao MY Yang M Kuang WH Qiu PY Department of Epidemiology and Biostatistics West China School of Public Health . Mental state examination in Chinese elderly people. J Peking Univ (Health Sci). (2015) 47:443–9. 10.3969/j.issn.1671-167X.2015.03.014

  • CrossRef
  • Google Scholar
  • View reference in article

• 28.

  Li F Bo QJ Zhao Y Liu H Wang CY The 3rd Ward of Beijing Anding Hospital . Quality of life and related factors in patients with major depressive disorde. J Cap Med Univ. (2017) 38:186–91. 10.3969/j.issn.1006-7795.2017.02.008

  • CrossRef
  • Google Scholar
  • View reference in article

• 29.

  ZhangQDaiCBWangWChenH. Study on the relationship between dementia and plasma homocysteine level. Pract Geria. (2017) 29:134–6. 10.3969/j.issn.1003-9198.2015.02.015

  • CrossRef
  • Google Scholar
  • View reference in article

• 30.

  Yuan QuanLXYaoWB. The demandations and factors for long-term care in institutions for disabled elderly. Chin J Gerontol. (2017) 6214–6. 10.3969/j.issn.1005-9202.2017.24.091

  • CrossRef
  • Google Scholar
  • View reference in article

• 31.

  WoolfCSlavinMJDraperBThomassenFKochanNAReppermundSet al. Can the clinical dementia rating scale identify mild cognitive impairment and predict cognitive and functional decline?Dement Geriatr Cogn Disord. (2016) 41:292–302. 10.1159/000447057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 32.

  KjeldsenSENarkiewiczKBurnierMOparilS. Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT memory and cognition IN decreased hypertension (SPRINT MIND) study. Blood Press. (2018) 27:247–8. 10.1080/08037051.2018.1507621

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 33.

  ZhuRLiuXHeZ. Association between CLU gene rs11136000 polymorphism and Alzheimer's disease: an updated meta-analysis. Neurol Sci. (2018) 39:679–89. 10.1007/s10072-018-3259-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 34.

  LiangXChenZDongXZhaoQGuoQZhengLet al. Mental work demands and late-life cognitive impairment: results from the Shanghai aging study. J Aging Health. (2019) 31:883–98. 10.1177/0898264318765034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 35.

  HouXHFengLZhangCCaoXPTanLYuJT. Models for predicting risk of dementia: a systematic review. J Neurol Neurosurg Psychiatry. (2019) 90:373–9. 10.1136/jnnp-2018-318212

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 36.

  JeffersonALCambroneroFELiuDMooreEENealJEet al. Higher aortic stiffness is related to lower cerebral blood flow and preserved cerebrovascular reactivity in older adults. Circulation. (2018) 138:1951–62. 10.1161/CIRCULATIONAHA.118.032410

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 37.

  OishiEOharaTSakataSFukuharaMHataJYoshidaDet al. Day-to-day blood pressure variability and risk of dementia in a general japanese elderly population: the Hisayama study. Circulation. (2017) 136:516–25. 10.1161/CIRCULATIONAHA.116.025667

  • CrossRef
  • Google Scholar
  • View reference in article

• 38.

  StreitSPoortvlietRKEGusseklooJ. Lower blood pressure during antihypertensive treatment is associated with higher all-cause mortality and accelerated cognitive decline in the oldest-old-data from the Leiden 85-plus study. Age Ageing. (2018) 47:545–50. 10.1093/ageing/afy072

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 39.

  MomtazYAHamidTAHaronSABagatMFMohammadiF. Prevalence of hypotension and its association with cognitive function among older adults. Aging Ment Health. (2018) 22:447–52. 10.1080/13607863.2016.1268093

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 40.

  van der WardtVBurtonJKConroySWelshTLoganPTaggarJet al. Withdrawal of antihypertensive therapy in people with dementia: feasibility study. Pilot Feasibility Stud. (2018) 4:29. 10.1186/s40814-017-0221-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 41.

  RileyDEEspayAJ. Cognitive fluctuations in Parkinson's disease dementia: blood pressure lability as an underlying mechanism. J Clin Mov Disord. (2018) 5:1. 10.1186/s40734-018-0068-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 42.

  PetekBVilla-LopezMLoera-ValenciaRGerenuGWinbladBKrambergerMGet al. Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementia. J Intern Med. (2018) 284:620–42. 10.1111/joim.12838

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 43.

  McGuinnessBToddSPassmorePBullockR. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. (2009) 2009:CD004034. 10.1002/14651858.CD004034.pub3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article